The Response to Chemotherapy of Serum Mycobacterium Leprae-Specific Antigen in Multibacillary Leprosy Patients

1991 ◽  
Vol 44 (6) ◽  
pp. 702-708 ◽  
Author(s):  
Paul W. Roche ◽  
Kapil Dev Neupane ◽  
Wim J. Theuvenet ◽  
Sang-Nae Cho ◽  
Warwick J. Britton ◽  
...  
Keyword(s):  
Specific Antigen ◽  
Mycobacterium Leprae ◽  
Response To Chemotherapy ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

scholarly journals Immunogold labeling method for Mycobacterium leprae-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and Araldite-embedded leprosy lesions.

1989 ◽  
Vol 37 (4) ◽  
pp. 455-462 ◽  
Author(s):  
J Boddingius ◽  
H P Dijkman
Keyword(s):  
Specific Antigen ◽  
Mycobacterium Leprae ◽  
Immunogold Labeling ◽  
Host Cells ◽  
Cell Mediated Immunity ◽  
Leprosy Patients ◽  
Skin Biopsies ◽  
Labeling Method ◽  
Multibacillary Leprosy ◽  
Swine Serum

Phenolic glycolipid (PGL)-I, a Mycobacterium leprae-specific antigen currently used for serodiagnosis of preclinical leprosy, has thus far not been localized subcellularly in leprosy bacilli and their host cells. In this study, we developed an immunogold-labeling technique for qualitative identification of PGL-I sites in glutaraldehyde-osmium-fixed and Araldite-embedded M. leprae and host macrophages in human skin biopsies. Such "hard-fixed," plastic-embedded skin and nerve biopsies from patients with varying cell-mediated immunity to leprosy are amply available worldwide. Our method involves etching of plastic sections with H2O2, incubation with swine serum to eliminate nonspecific labeling, and long (22 hr) incubation at room temperature with monoclonal antibodies to PGL-I. Gold labeling was seen predominantly on cell walls of M. leprae, in vacuolar spaces of bacillated phagolysosomes, and occasionally on the cytoplasm and cell membrane of M. leprae. Host macrophage cytoplasm was labeled very infrequently. This technique allows studies on possibly persisting antigenic PGL-I in multibacillary leprosy patients during or after multidrug therapy. The method may also prove useful for subcellular localization of specific bacterial lipids in other mycobacterial diseases, including tuberculosis.

Analysis of the Myeloid-Derived Suppressor Cells and Annexin A1 in Multibacillary Leprosy and Reactional Episodes

2020 ◽  
Author(s):  
Amilcar Sabino Damazo ◽  
Stephanni Figueiredo da Silva ◽  
Leticia Rossetto da Silva Cavalcante ◽  
Ezequiel Angelo Fonseca Junior ◽  
Joselina Maria da Silva ◽  
...  
Keyword(s):  
Suppressor Cells ◽  
Suppressor Cell ◽  
Mycobacterium Leprae ◽  
Histopathological Analysis ◽  
Annexin A1 ◽  
Myeloid Derived Suppressor Cells ◽  
Myeloid Derived Suppressor Cell ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

Abstract Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Patients have distinct clinical forms, and host´s immunological response regulate those manifestations. In this work, the presence of the myeloid-derived suppressor cell and the regulatory protein annexin A1 is described in patients with multibacillary leprosy and with type 1 and 2 reactions. Methods: Patients were submitted to skin biopsy for histopathological analysis to obtain bacilloscopic index. Immunofluorescence was used to detect myeloid-derived suppressor cells and annexin A1.Results: The data demonstrated that the presence of granulocytic and monocytic myeloid-derived suppressor cells in leprosy patients. The high number of monocytic myeloid-derived suppressor cells were observed in lepromatous leprosy and type 2 reactional patients with Bacillus Calmette–Guérin (BCG) vaccination scar. The presence of annexin A1 was observed in all myeloid-derived suppressor cells. In particularly, the monocytic myeloid-derived suppressor cell in the lepromatous patients has higher levels of this protein when compared to the reactional patients. This data suggest that the higher expression of this protein may be related to regulatory response against a severe infection, contributing to anergic response. In type 1 reactional patients, the expression of annexin A1 was reduced. Conclusions: Myeloid-derived suppressor cell are present in leprosy patients and annexin A1 might be regulated the host response against Mycobacterium leprae.

scholarly journals Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy

2008 ◽  
Vol 52 (9) ◽  
pp. 3113-3117 ◽  
Author(s):  
Fe Eleanor F. Pardillo ◽  
Jasmin Burgos ◽  
Tranquilino T. Fajardo ◽  
Eduardo Dela Cruz ◽  
Rodolfo M. Abalos ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Bactericidal Activity ◽  
Mycobacterium Leprae ◽  
Skin Lesions ◽  
Definite Improvement ◽  
Highly Effective ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

ABSTRACT In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P ≤ 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.

scholarly journals Mycobacterium leprae is identified in the oral mucosa from paucibacillary and multibacillary leprosy patients

2014 ◽  
Vol 20 (1) ◽  
pp. 59-64 ◽  
Author(s):  
M.A.M. Morgado de Abreu ◽  
A.M. Roselino ◽  
M. Enokihara ◽  
S. Nonogaki ◽  
L.E. Prestes-Carneiro ◽  
...  
Keyword(s):  
Oral Mucosa ◽  
Mycobacterium Leprae ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

scholarly journals Clinical profile and deformities in leprosy patients: a record based study

2020 ◽  
Vol 6 (2) ◽  
pp. 156
Author(s):  
Anita Sanker ◽  
Sandhya George ◽  
Sindhu Chunangat Bhaskaramenon
Keyword(s):  
Public Health Problem ◽  
Mycobacterium Leprae ◽  
Clinical Profile ◽  
Current Status ◽  
Age Group ◽  
Medical College ◽  
Tribal Area ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

<p class="abstract"><strong>Background:</strong> Leprosy is a chronic disease caused by <em>Mycobacterium leprae</em>, infectious in some cases, and affecting the peripheral nervous system, skin and certain other tissues. Even though leprosy was declared eliminated as a public health problem in India on December 2005, new cases of leprosy continue to appear. Hence a study on clinical profile and deformities in all leprosy cases registered in the last 5 years was done to know the current status of leprosy in this area.</p><p class="abstract"><strong>Methods: </strong>This was a retrospective record-based study of leprosy cases done at Government Medical College, Manjeri, for a period of 5 years from October 2014 to September 2019.<strong></strong></p><p class="abstract"><strong>Results:</strong> 42 cases from the record were included in the study. Maximum cases belonged to the age group of 31 to 40 and males were more than females. 81% of the patients were multibacillary leprosy (MB) and 8 cases belonged to paucibacillary (PB) leprosy. Four child cases were registered as PB cases. Mostly encountered clinical diagnosis was borderline tuberculoid leprosy (23 out of 42) and two had type 1 reaction. Seven patients had deformity of which two had grade 2 deformity and rest had grade 1 deformity.</p><p><strong>Conclusions:</strong> One patient who presented with grade 2 deformity and type 1 reaction was from tribal area indicating low awareness about leprosy among them. More number of cases in the multibacillary group and presence of child cases and deformities reinforces the need for strict surveillance to eradicate leprosy. </p>

scholarly journals Analysis of the myeloid-derived suppressor cells and annexin A1 in multibacillary leprosy and reactional episodes

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stephanni Figueiredo da Silva ◽  
Leticia Rossetto da Silva Cavalcante ◽  
Ezequiel Angelo Fonseca Junior ◽  
Joselina Maria da Silva ◽  
José Cabral Lopes ◽  
...  
Keyword(s):  
Suppressor Cells ◽  
Suppressor Cell ◽  
Mycobacterium Leprae ◽  
Histopathological Analysis ◽  
Annexin A1 ◽  
Myeloid Derived Suppressor Cells ◽  
Myeloid Derived Suppressor Cell ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

Abstract Background Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Patients have distinct clinical forms, and the host´s immunological response regulate those manifestations. In this work, the presence of the myeloid-derived suppressor cell and the regulatory protein annexin A1 is described in patients with multibacillary leprosy and with type 1 and 2 reactions. Methods Patients were submitted to skin biopsy for histopathological analysis to obtain a bacilloscopic index. Immunofluorescence was used to detect myeloid-derived suppressor cells and annexin A1. Results The data demonstrated that the presence of granulocytic and monocytic myeloid-derived suppressor cells in leprosy patients. A high number of monocytic myeloid-derived suppressor cells were observed in lepromatous leprosy and type 2 reactional patients. The presence of annexin A1 was observed in all myeloid-derived suppressor cells. In particular, the monocytic myeloid-derived suppressor cell in the lepromatous patients has higher levels of this protein when compared to the reactional patients. This data suggest that the higher expression of this protein may be related to regulatory response against a severe infection, contributing to anergic response. In type 1 reactional patients, the expression of annexin A1 was reduced. Conclusions Myeloid-derived suppressor cell are present in leprosy patients and annexin A1 might be regulated the host response against Mycobacterium leprae.

scholarly journals Detection of antibodies against Mycobacterium leprae culture filtrate protein-10 in leprosy patients

2006 ◽  
Vol 55 (10) ◽  
pp. 1337-1341 ◽  
Author(s):  
Om Parkash ◽  
Ajay Kumar ◽  
Astha Nigam ◽  
Bhawneshwar K. Girdhar
Keyword(s):  
Antibody Response ◽  
Culture Filtrate ◽  
Specific Antigen ◽  
Mycobacterium Leprae ◽  
Serum Samples ◽  
Leprosy Patients ◽  
Infectious Form ◽  
Culture Filtrate Protein ◽  
Bacterial Index

The prevalence of IgG antibodies against Mycobacterium leprae recombinant culture filtrate protein-10 (rCFP-10) was investigated in serum samples from 56 leprosy patients, 15 tuberculosis (TB) patients, 14 other skin-diseased patients and 20 healthy subjects. On classifying the patients into bacterial index (BI)-positive and BI-negative groups, the assay showed 83.3 % (15/18) sensitivity for detection of BI-positive leprosy patients. On the other hand, the sensitivity for detection of BI-negative patients was 18.4 % (7/38). None of the 15 TB patients and 14 other skin-diseased patients was positive; however, only one out of 20 healthy individuals was positive, indicating that antibody response to culture filtrate protein-10 (CFP-10) was highly specific (98.0 %; 48/49). Statistically, the performance of the CFP-10-based assay was found to be comparable (P>0.05) with that of an anti-phenolic glycolipid-I (PGL-I) antibody-detecting assay. Thus, M. leprae CFP-10 is potentially a specific antigen for measuring antibody response in BI-positive leprosy patients. Being a secreted antigen, CFP-10 may act as a marker for the viability of M. leprae inside the host, and hence its serological potential is worth exploring for application in monitoring the response of patients with BI-positive leprosy (a highly infectious form) during the course of chemotherapy. When comparing the bacteriological and serological results, an agreement of 82.1 % showed that seropositivity to M. leprae CFP-10 corresponded well with bacteriological criteria. Hence, CFP-10 seems to be a suitable antigen for classification of leprosy patients into BI-positive and BI-negative groups.

Sign in / Sign up

Export Citation Format

Share Document